{"id":"W4365136161","doi":"10.1182/bloodadvances.2022009311","title":"Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; AOP Orphan; Italfarmaco; Angelini Pharma; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Jazz Pharmaceuticals; Gilead Sciences; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Constellation Pharmaceuticals","keywords":"Ruxolitinib; Discontinuation; Medicine; Anemia; Internal medicine; Randomized controlled trial; Myelofibrosis; Neutropenia; Adverse effect; Gastroenterology; Bone marrow; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003645369,0.0002950824,0.007019347,0.0008947507,0.00005008682,0.00002316968,0.00006097803,0.00008181392,0.0001984438],"category_scores_gemma":[0.003928997,0.0001710149,0.0008287543,0.001628988,0.0001530622,0.0001045946,0.00002853303,0.0001045667,0.000004707581],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002296644,"about_ca_system_score_gemma":0.00008233074,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004954388,"about_ca_topic_score_gemma":0.0002949012,"domain_scores_codex":[0.996275,0.0009844875,0.001733034,0.0003996829,0.0003461133,0.0002617],"domain_scores_gemma":[0.9930919,0.005800327,0.0006040439,0.0002162261,0.0001632499,0.000124301],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.419762,0.002634919,0.5288193,0.0002039835,0.02669019,0.0001849694,0.0006382072,0.0002079544,0.002955886,0.0006630491,0.00001166599,0.01722779],"study_design_scores_gemma":[0.8304512,0.0005755022,0.1402664,0.0003669453,0.01995399,0.000003582984,0.0002512236,0.001284906,0.006526733,0.00005725297,0.00007337953,0.0001888959],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9876208,0.008462559,0.0001161946,0.0004725421,0.0001260949,0.002560453,0.0001649647,0.00006614363,0.0004102915],"genre_scores_gemma":[0.9804388,0.01800636,0.0002507927,0.00003988844,0.00004828935,0.0005358171,0.0003607633,0.00001689998,0.0003024244],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4106892,"threshold_uncertainty_score":0.6973786,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02911296920830965,"score_gpt":0.359403814225357,"score_spread":0.3302908450170474,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}